Biopharmaceutical firm SAGE Therapeutics scored USD 20 million from ARCH Venture Partners and Third Rock Ventures in its Series B funding round.
ARCH Venture Partners
Breaking News
- Beijing Offers Subsidies for Companies That Buy Local AI Chips as China Cuts Reliance on Foreign Technology
- Businessman Who Shot His Wife to Death Thinking She Was an Intruder Gets Only 12 Years in Prison
- US Secretary of State Antony Blinken Calls on China to Treat American Companies Fairly During Visit to Shanghai
bluebird bio today announced the successful completion of a $60 million Series D financing.
Subscribe to VCpost newsletter
Most Popular
- SSI Payment for May 2024: Supplemental Security Income Recipients to See Double Amount in Payout
- Doctors Raise Concerns Over Proposed Capital Gains Tax Changes
- How to Get IRS Unclaimed Tax Refunds: Here's What to Do If You Think You Have Pending Payments
- How to Apply for Social Security Spousal Benefits; Here's How You May Boost Your Money!
- JPMorgan CEO Warns of Economic Risks Amid Biden's 'Huge' Deficit Spending, Questions Likelihood of 'Soft Landing'
- MSC Darwin Ship Targeted by Yemen's Houthis in Gulf of Aden
- Norway Airspace Shuts Down for Several Hours Following Technical Glitch
- Google's Parent Company Alphabet Approves First-Ever Dividend as Shares Skyrocket
